Triple-negative breast cancers (TNBCs) lack the signature targets of other breast tumors, such as HER2, estrogen receptor, and progesterone receptor. These aggressive basal-like tumors are driven by a complex array of signaling pathways that are activated by multiple driver mutations. Here we report the discovery of 6 (KIN-281), a small molecule that inhibits multiple kinases including maternal leucine zipper kinase (MELK) and the non-receptor tyrosine kinase bone marrow X-linked (BMX) with single-digit micromolar IC 50 s. Several derivatives of 6 were synthesized to gain insight into the binding mode of the compound to the ATP binding pocket. , and cyclin A2 levels. Finally, LC3B-II levels were quantified following treatment of cells with 6 to determine whether the compound affected autophagy, a process that is known to be activated by STAT3. Compound 6 provides a starting point for the development of small molecules with polypharmacology that can suppress TNBC growth and metastasis.
INTRODUCTION
Triple-negative breast cancer (TNBC) has taken on added importance in recent years as it is characterized by poor prognosis, aggressive behavior, and a lack of specific targets such as ER, HER2, or progesterone receptor. Although chemotherapy is effective for TNBC patients in the adjuvant setting, chemotherapy-resistant TNBC is quickly fatal given its rapid growth and lack of targeted therapies. TNBC accounts for approximately 15% of breast cancer cases in the United States. Despite its lower incidence, TNBC contributes disproportionately to breast cancer morbidity and mortality compared to other breast cancer subtypes. This can be attributed in part to its intrinsic aggressiveness, but much of the excess mortality is due to the absence of effective targeted therapies. New targets and small molecules to probe these targets are needed for the development of effective therapeutic agents for the treatment of TNBC 1 .
Unlike other subtypes of cancer, hormone therapy or biologics such as trastuzumab have little effects on TNBC tumors. There is currently an intense search for vulnerabilities of this breast cancer sub-type that can be exploited for the development of targeted therapeutic agents. To identify new targets that suppress growth and metastasis of TNBC tumors, we previously screened a commercial library of small molecules using structure-based molecular docking. The focus was on members of the CaMK superfamily of kinases, which are relatively unexplored in cancer. We identified 1, a small molecule that inhibited CaMKIIδ with single-digit micromolar IC 50 s. Kinome-wide profiling against 337 kinases confirmed that CaMKIIδ was among the top 10 targets of the compound, along with other members of the CaMK family, such as the maternal embryonic zipper leucine kinase (MELK), and the non-receptor tyrosine kinase bone marrow X-linked (BMX).
The inhibition of multiple kinases by 1 prompted us to explore the compound and several of its derivatives in TNBC breast cancer cell lines MDA-MB-468 and MDA-MB-231. We focused on 6 (KIN-281). The compound was tested for activity in a panel of 25 kinases. We explored the effects of the compound on cell viability and colony formation in anchorage-dependent and independent assays. We further explored the effect of compounds on pro-apoptotic survivin and Bcl-X L , as well as cell cycle protein cyclin-dependent kinase inhibitor 1 (p21 WAF1/CIP1 ).
Considering the effect on BMX and Bcl-X L we examined the effects of the compound on signal transducer and activator of transcription 3 (STAT3) as well as autophagy, which is activated by STAT3. Soft Agar Assay for Colony Formation. 0.5 mL base layer of 0.5% agar in DMEM medium containing 10% fetal bovine serum was placed in 24-well plates and permitted to solidify at room temperature. Cells to be tested for colony formation were suspended in the top layer (0.5 mL) of 0.3% agar in DMEM medium with 10% fetal bovine serum. The agar was permitted to solidify at room temperature. 0.25 mL feeding medium was added on the top layer with 1% DMSO (control) or compounds at the indicated concentrations for 10 d at 37°C in a humidified incubator in an atmosphere of 5% CO 2 . The feeding medium was change twice a week. Cell colonies were stained with 0.005% Crystal Violet and inspected with a dissecting microscope. Autophagy Assays. Bafilomycin A1 (Enzo) was added at 100 nM for 4 hours before harvest of cells. Cells were lysed in NP40 buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1% NP40) with protease and phosphatase inhibitors. Lysates were centrifuged at 16,300xg for 15 min at 4°C; supernatants were separated by SDS-PAGE. After transfer to PVDF, membranes were blocked in 5% milk/PBS for 1 hr at RT and incubated at 4°C overnight with primary anti-LC3B antibody from Novus (cat# NB600-1384) at 1:3,000 in 5% milk/PBS.
MATERIALS AND METHODS

Cell
Electrophoresis Mobility Shift Assay (EMSA
Membranes were washed 3x in PBS-T 0.05% Tween and then incubated for 2 hrs with secondary (anti-rabbit HRP, 1:10,000) at RT. Membranes were washed 2x in PBS-T 0.05% Tween. Detection was performed by enhanced chemiluminescence after 2-h incubation with HRP-conjugated secondary antibodies (Dako).
Virtual Screening. The program Glide from Schrödinger (Schrödinger LLC, New York, NY, 2010) was used for molecular docking of 6 to the MELK ATP binding pocket. Glide is a robust docking program that has been extensively validated in previous studies. The structures of 6 was prepared using LigPrep in Schrödinger. Compound was protonated at pH 7. The structure of MELK (PDB ID: 4CQG, 2.57 Å) was prepared for docking. Grid boxes were generated for the three proteins for docking in Glide, with a box size of 21 Å and an inner box of 14 Å. All other parameters were set to default values. A series of binding poses were generated by docking 6 and its derivatives against the ATP binding site of each of the three proteins using Glide in standard precision (SP) mode. All other parameters were left to default values.
General Synthesis Methods. All chemicals were purchased from either Sigma-Aldrich or Acros Organics. Column chromatography was carried out with silica gel G (25-63µm). Mass Spectra were measured on an Agilent 6520 Mass Q-TOF instrument. reagents were all analytically pure and dried through routine protocols. All compounds that were evaluated in biological essays had > 95% purity verified by HPLC. 
2-methyl-6-nitroquinazolin-4(3H)-one (6a
6-nitro-2-(2, 4, 6-trichlorostyryl)quinazolin-4(3H)-one (6c).
A solution of 6a (205 mg, 1 mmol) and 6b (210 mg, 1mmol) in acetic acid (3 mL) was refluxed for 30 h. The mixture was cooled to room temperature, and the precipitate was filtered and washed with methanol (2 mL x 3). The filter cake was collected to give the desired product as a yellow solid (329 mg, 83 % yield We purchased additional analogs of 1 (compounds 2-15) and tested several compounds for inhibition of MELK (Fig. 1a) . Compound 6 showed the most potent activity with more than 98% inhibition at 20 µM. To identify additional targets for 6, we tested whether the compound inhibited the activity of the top 25 kinase targets of compound 1 that were identified from a previous profiling of 337 kinases (Fig. 1b) . We found that 6 inhibits kinases with IC 50 values ranging from 1.4 ± 0.9 µM for MELK to 42.7 ± 4.6 µM for FER kinase. Compound 6 inhibited two other kinases with an IC 50 less than 2 µM, namely BMX/ETK (1.9 ± 0.6 µM) and TIE2/TEK (1.8 ± 0.9 µM).
To explore the role of each substituent of 6 on the inhibition of MELK activity, we prepared 9 derivatives of the compound (Scheme 2, Scheme 3, and Fig. 1c) . The role of the amine at R 2 was investigated by replacing it with a methoxy group affording compound 16. The compound was three-fold weaker than 6 suggesting that the amino group was engaged in favorable interactions likely through hydrogen bonding (Fig. 1d) . 
Scheme 3.
Synthesis of 21.
Compounds Inhibit Cancer Cell Growth in Anchorage-Dependent and Independent
Assays. Considering that the kinases inhibited by the compound are known to be up-regulated in various basal-like breast tumors, we explored the effect of 1-15 on breast MDA-MB-231 cell viability (Fig. 2) . Most of the compounds inhibited breast MDA-MB-231 cell growth with IC 50 values that ranged from 2 to 30 µM (Fig. 2a) . Compounds Up-regulate p21 WAF1/CIP1 in a p53-dependent Manner. Previous studies had shown that MELK contributes to cell cycle progression by causing G/M arrest 3, 4 , and reduced the number of cells at the G 2 /M transition 4, 5 . These studies also showed that knockdown of MELK resulted in up-regulation of p21
in U87 GBM cell lines 4 . We observed the same effect for 1 (KIN-1) and 6 (KIN-281); at 5 µM, the compound up-regulated
in MDA-MB-468 ( Fig. 3a and 3b) and MDA-MB-231 ( Fig. 3c and 3d) . A timedependent study was conducted with both of these cell lines. After 4 h, both 1 (KIN-1) and 6
. The effect on p21
was sustained over 48 h in both cell lines. We investigated the effects of p21
on cyclins, which are inhibitors of p21 WAF1/CIP1
. We found that an increase in p21
corresponded closely to a decrease in cyclin A2, which was gradually down-regulated over the course of 48 h (Fig. 3a to 3d) .
is a p53 target gene, treatment of MDA-MB-468 cells with 1 (KIN-1) and 6 (KIN-281) showed no effect on p53 levels over 48 h (Fig. 3e) . We investigated whether the compounds had any effects on p53 phosphorylation, particularly at Ser15, which has been previously found to be affected by MELK suppression. Phosphorylation at Ser15 inhibits the interaction of p53 with its antagonists MDM2 or MDMX, which de-stabilize p53 and inhibit apoptosis. Interestingly, both compounds inhibited phosphorylation at Ser15 of p53 consistent with a potential effect on MELK activity (Fig. 3f) . 
Compounds Block STAT3 and Down-regulate Pro-Apoptotic Markers Survivin and
Bcl-XL. Both 1 (KIN-1) and 6 (KIN-281) inhibited STAT3 phosphorylation in MDA-MB-468 ( Fig.   4a and 4b) and MDA-MB-231 ( Fig. 4c and 4d ) cells. A time course revealed that STAT3 phosphorylation was completely inhibited at 4 h, but phosphorylation levels were restored after 8 h in MDA-MB-468 cells. A similar observation was made in MDA-MB-231 except that these cells recover STAT3 phosphorylation levels more slowly. The effect on STAT3 phosphorylation was confirmed with electrophoresis mobility shift assay (EMSA), which showed that 1 (KIN-1) inhibited STAT3 dimer binding to DNA (Fig. 4e) . It is of interest to note that JAK kinase activity was not affected by our compounds as evidenced by the lack of inhibition of JAK kinase activity by 6 (Fig. 4f) . This suggests that the inhibitors are following a non-canonical pathway to blocking STAT3. Previous studies have suggested that BMX promotes STAT3 activation through the PI3K pathway in a manner that is independent of Akt 6
. We find that 1 (KIN-1) or 6
(KIN-281) had no effect on Akt phosphorylation ( Fig. 4g and 4h) .
It is often the case that STAT3 phosphorylation leads to down-regulation of survivin 7, 8 .
Survivin is a member of the XIAP (X-linked inhibitor of apoptosis) group of proteins. Studies have shown that survivin works in a complex mechanism to promote cell growth and to inhibit apoptosis. Survivin is a component of the chromosomal passenger complex (CPC) and hence has a critical role cell cycle progression and cell proliferation 9, 10 11, 12 . Interestingly, 1 (KIN-1) and 6 (KIN-281) led to down-regulation of survivin in MDA-MB-468 ( Fig. 4a and 4b ) and MDA-MB-231 ( Fig. 4c and 4d) . The effect was sustained over the course of 48 h in both MDA-MB-468 and MDA-MB-231. Interestingly, both 1 and 6 also reduced expression of the pro-apoptotic protein Bcl-XL ( Fig. 4a-d) . [16] [17] [18] . BMX is a member of the Tec non-receptor tyrosine kinase family. MELK has been identified as an important target for other epithelial tumors including colorectal, lung, breast, ovarian and brain 19 . High expression of MELK in cancer stem cells has also been found 20, 21 . MELK is overexpressed in basal-like breast cancer and several studies have implicated the enzyme with tumor growth and metastasis 4, 22 . The inhibition of MELK, BMX and other kinases by 6 may explain its effect in TNBC cancer cells.
Some of the effects that we observed for 6 (KIN-281) may be partly associated with inhibition of MELK or BMX. MELK plays an important role in cell cycle [23] [24] [25] [26] . Previous studies have shown that knockdown of MELK in U87 led to p21 . Studies that have suggested that the effect on p21
is a p53-dependent process have been conflicting. One study has shown that MELK suppression has no effect on Ser15 phosphorylation in U87 or levels of p53, suggesting instead that the effect on p53 may be due to MDMX down-regulation rather than an effect on p53 4 . Another study found that suppressing MELK led to inhibition of Ser15 phosphorylation and increased stabilization of p53 27 . 1 (KIN-1) and 6 (KIN-281) had no effect on the levels of p53 in agreement with both studies.
However, the compound inhibited Ser15 phosphorylation in a time-dependent fashion consistent with the results of Seong and co-workers 27 . We investigated the effect of the compounds on MDMX levels and observed an increase in MDMX, consistent with the observation of Seong and co-workers with MDM2 . This process was found to be independent of JAK kinases, which are generally associated with STAT3 activation 29 .
The inhibition BMX by 6 prompted us to explore whether STAT3 phosphorylation is affected in both MDA-MB-231 and MDA-MB-468. STAT proteins have dual roles: they transduce signals through the cytoplasm and function as transcription factors in the nucleus 30, 31 . Following phosphorylation from specific tyrosine kinases, STATs form stable homodimers, sometimes heterodimers, through SRC homology 2 (SH2) domain interactions. In the nucleus, a STAT3 dimer complex bind to DNA and modulate the transcription of genes that play a critical role in promoting inflammatory and malignant processes. The effects on STAT3 went beyond merely inhibition of phosphorylation of the transcription factor. We found through EMSA that 1 (KIN-1) inhibited STAT3 DNA-binding. This suggests that the compound is likely also affecting STAT3 transcription factor activity. However, compound 6 had no effect on JAK kinases suggesting that inhibition of STAT3 occurs through another mechanism, possibly through PI3K by activation of BMX. A recent study has shown that phosphorylation of STAT3 in PI3K-transformed cells is driven by BMX 6 . The study demonstrates that instead of the usual PIP3/Akt/mTOR pathway, PIP3 leads to phosphorylation of BMX, which in turn phosphorylates STAT3 and leads to oncogenic phenotype (Fig. 6) . In fact,
we tested the effects of the compounds on Akt phosphorylation and found no effect confirming that the compound does not affect the PI3K/Akt/mTOR pathway.
We found that the compounds also suppressed the levels of pro-apoptotic survivin and Bcl-XL. Although survivin is often associated with apoptosis, it is a cell cycle protein that is highly up-regulated in cancer versus normal cells. Survivin has multiple functions. Initially thought to be strictly involved in programmed cell death, survivin has been shown to play a key role in cell cycle progression and cell proliferation. In fact, survivin is required for several stages of cell division. At metaphase, it localizes to kinetochores then transfers to the central spindle mid-zone at anaphase, and finally accumulates in mid-bodies at telophase . Previous studies have shown that STAT3 promotes autophagy through a complex with PKR (Fig. 6) 
14
. Autophagy is a highly conserved self-degradative process that plays a critical role in cellular stress response and survival mechanisms. Cells use autophagy to turnover damaged organelles, pathogens and large protein aggregates. This degradation process provides a critical source of amino acids, nucleotides, and fatty acids, especially for cancer cells, which are generally unable to acquire sufficient nutrients to sustain the ATP production required for these cells to survive. A commonly used marker for autophagy is LC3B-II 15 . We found that 6 (KIN-281) led to a significant increase in LC3-II levels suggesting that MELK may play a role in suppressing autophagy. The effects of the compound at 5 µM were as pronounced as bafilomycin A1, a well-known late-stage autophagy inhibitor. Inhibition of autophagy may have benefits for cancer treatment, particularly breast cancer where autophagy may help cells evade apoptosis 35, 36 . Beyond cell survival, accumulating evidence suggests that autophagy is involved in nearly every step of the metastatic cascade. In fact, 50% of human breast cancers exhibit heterozygous deletion of beclin-1, which is critical for autophagosome formation 37, 38 . By inhibiting autophagy, these compounds may thus have a beneficial effect for TNBC patients by limiting progression of disease. activation leads to eIF2A phosphorylation and autophagy.
